MedTrace Logo

CARESS in Acute Myocardial Infarction

NCT00220571 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2007-07-03

No results posted yet for this study

Summary

The aim of this study conducted in patients with high risk ST-segment elevation AMI admitted to hospitals with no PTCA facilities is to compare the effects on clinical outcome and cost-effectiveness of two reperfusion strategies:

* Fibrinolytic therapy with Abciximab and half-dose Reteplase, with rescue PTCA in case of lack of reperfusion
* Elective referral for "facilitated" PTCA after early administration of Abciximab and half dose of Reteplase

Conditions

Interventions

DEVICE

Coronary Angioplasty (PTCA)

Sponsors & Collaborators

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Biotronik SE & Co. KG

    collaborator INDUSTRY

  • Società Italiana di Cardiologia Invasiva

    lead OTHER

Principal Investigators

  • Leonardo Bolognese, MD, Ph D · Ospedale San Donato - Arezzo Italy

  • Gabriel P. Steg, MD. Ph D · Hopital Bichat - Paris France

  • Darius Dudek, MD, Ph D · Jagellonian University Krakow Poland

  • Carlo Di Mario, MD · Royal Brompton and Harefield Hospital - London UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Completion
2007-03-31

Countries

  • France
  • Italy
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220571 on ClinicalTrials.gov